Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States

Value in Health ◽

10.1016/j.jval.2018.04.1400 ◽

2018 ◽

Vol 21 ◽

pp. S206

Author(s):

D Rao ◽

E Heidari ◽

KM Kamal ◽

AA Dashputre

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

Journal of Medical Economics ◽

10.3111/13696998.2012.693553 ◽

2012 ◽

Vol 15 (6) ◽

pp. 1088-1096 ◽

Author(s):

Soyon Lee ◽

Daniel C. Baxter ◽

Brendan Limone ◽

Matthew S. Roberts ◽

Craig I. Coleman

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND44 Assessing Variations in Transitions in Employment in Relapsing-Remitting Multiple Sclerosis Patients Treated With Either Laquinimod, Interferon Beta 1-a or Placebo: Expoloratory Evidence From the United States Substudy of Bravo

Value in Health ◽

10.1016/j.jval.2012.03.803 ◽

2012 ◽

Vol 15 (4) ◽

pp. A149

Author(s):

C.A. Carroll ◽

M.A. Oleen-Burkey

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

Journal of Medical Economics ◽

10.3111/13696998.2016.1157080 ◽

2016 ◽

Vol 19 (7) ◽

pp. 684-695 ◽

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Elizabeth Kinter ◽

Monica Fay

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Treatment patterns of relapsing remitting multiple sclerosis (RRMS) in Europe and the United States

10.26226/morressier.59a3edacd462b8028d8958b7 ◽

2017 ◽

Author(s):

Joanna White

Keyword(s):

United States ◽

Multiple Sclerosis ◽

The United States ◽

Treatment Patterns ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Characteristics of Patients with Relapsing Remitting Multiple Sclerosis Taking Injectable and Oral Disease Modifying Treatments in the United States

Value in Health ◽

10.1016/j.jval.2014.08.933 ◽

2014 ◽

Vol 17 (7) ◽

pp. A404-A405

Author(s):

S. Narayanan ◽

P. O'Meara ◽

J. White ◽

J. Chan ◽

S. Gabriele

Keyword(s):

United States ◽

Multiple Sclerosis ◽

The United States ◽

Oral Disease ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

Value in Health ◽

10.1016/s1098-3015(11)70789-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 362-363

Author(s):

E Orlewska ◽

P Mierzejewski ◽

A Czlonkowska

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Comparison of Patients With Relapsing Remitting Multiple Sclerosis (Rrms) Treated With Disease Modifying Treatments (Dmt) In Europe (Eu) And The United States (Us)

Value in Health ◽

10.1016/j.jval.2015.09.2513 ◽

2015 ◽

Vol 18 (7) ◽

pp. A766

Author(s):

S Narayanan ◽

P O’Meara ◽

J White ◽

J Chan ◽

R Hooper ◽

...

Keyword(s):

United States ◽

Multiple Sclerosis ◽

The United States ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Heatlh Care Costs Associated with Patients Diagnosed with Relapsing Remitting Multiple Sclerosis Taking Once Daily Teriflunomide Tablets in the United States

Value in Health ◽

10.1016/j.jval.2015.09.054 ◽

2015 ◽

Vol 18 (7) ◽

pp. A878

Author(s):

N Greene ◽

M Greene

Keyword(s):

United States ◽

Multiple Sclerosis ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis ◽

Download Full-text

Patterns of Use of Tests to Monitor Disease Activity Among Patients With Relapsing Remitting Multiple Sclerosis in the United States and Europe

Value in Health ◽

10.1016/j.jval.2014.08.929 ◽

2014 ◽

Vol 17 (7) ◽

pp. A404

Author(s):

S. Narayanan ◽

P. O'Meara ◽

J. White ◽

J. Chan ◽

S. Gabriele

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Disease Activity ◽

The United States ◽

Patterns Of Use ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text